PCSK9 Revised Analysis Indicates Less Price Discounting May Be Needed
This article was originally published in The Pink Sheet Daily
A change in projected discounts resulted from ICER’s decision to broaden its consideration of the benefit of PCSK9 treatment to span a patient’s lifetime, including outcomes in patients over 75.
You may also be interested in...
Amgen Faces New ICER Roadblock To Repatha Reimbursement
The Institute for Clinical and Economic Review is lowering the value-based pricing benchmark for Amgen's PCSK9 inhibitor based on the results of the FOURIER cardiovascular outcomes trial – which was positive overall but did not show a reduction in CV mortality.
Repatha Pricing Pressure Might Actually Increase After Outcomes Trial
Amgen's FOURIER study prompts ICER to plan new value-based price benchmark for Repatha below its previously recommended range of $5,404 to $7,735 per year.
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.